Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Circ Genom Precis Med. 2022 May 18;15(4):e003527. doi: 10.1161/CIRCGEN.121.003527

Table 2.

Likely pathogenic and pathogenic variants in both Tier 1 and Tier 2 genes

Case Gene Nucleotide variant Amino acid variant ACMG classification* gnomAD MAF^ Varsome ACMG criteria
Tier 1
090 ALDH18A1 NM_002860.4:c.1367G>A p.Arg456His Likely pathogenic 0.00004600 PM1, PM2, PP2, PP3
146 COL3A1 NM_000090.3:c.2798dupG p.Ser934IlefsTer35 Pathogenic - PVS1, PM2, PP3
171 COL4A1 NM_001845.6:c.3592G>A p.Gly1198Arg Likely pathogenic - PM1, PM2, PP2, PP3
170 COL4A1 NM_001845.6:c.4877C>G p.Ala1626Gly Likely pathogenic 0.00000707 PM1, PM2, PP2, PP3
115 FBN1 NM_000138.4:c.793A>T p.Thr265Ser Likely pathogenic - PM1, PM2, PP2, PP3
004 FBN1 NM_000138.4:c.256C>T p. Arg86Trp Likely pathogenic 0.00001195 PM1, PM2, PP2, PP3
Tier 2
090 ACVR1 NM_001111067.4:c.1298A>G p.Asp433Gly Likely pathogenic 0.00000398 PM1, PM2, PP2, PP3
091 ACVR1 NM_001111067.4:c.1265G>A p.Gly422Asp Likely pathogenic - PM1, PM2, PP2, PP3

ACMG, American College of Medical Genetics; MAF, minor allele frequency.

*

ACMG classifications are automatically derived from Varsome and manually evaluated

^

gnomAD MAF refers to all populations.

ACMG interpretation criteria, detailed in Supplementary Table XV